G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 127 filers reported holding G1 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $133,357 | -39.7% | 17,547 | -19.1% | 0.00% | – |
| Q4 2021 | $221,000 | -22.5% | 21,690 | +2.1% | 0.00% | – |
| Q3 2021 | $285,000 | -42.3% | 21,246 | -5.6% | 0.00% | – |
| Q2 2021 | $494,000 | +3.1% | 22,508 | +13.0% | 0.00% | – |
| Q1 2021 | $479,000 | +28.1% | 19,915 | -4.1% | 0.00% | – |
| Q4 2020 | $374,000 | +57.8% | 20,767 | +1.0% | 0.00% | – |
| Q3 2020 | $237,000 | -52.3% | 20,554 | 0.0% | 0.00% | – |
| Q2 2020 | $497,000 | +106.2% | 20,554 | -6.2% | 0.00% | – |
| Q1 2020 | $241,000 | -55.5% | 21,909 | +6.8% | 0.00% | -100.0% |
| Q4 2019 | $542,000 | -24.4% | 20,516 | -2.8% | 0.00% | 0.0% |
| Q3 2019 | $717,000 | +10.1% | 21,116 | -0.5% | 0.00% | 0.0% |
| Q2 2019 | $651,000 | -10.3% | 21,219 | +52.7% | 0.00% | 0.0% |
| Q3 2018 | $726,000 | +7.7% | 13,892 | -10.4% | 0.00% | 0.0% |
| Q2 2018 | $674,000 | +68.1% | 15,507 | +43.6% | 0.00% | – |
| Q1 2018 | $401,000 | +190.6% | 10,800 | +54.9% | 0.00% | – |
| Q4 2017 | $138,000 | -19.3% | 6,974 | +1.2% | 0.00% | – |
| Q3 2017 | $171,000 | – | 6,894 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |